TRP channels and psychiatric disorders

Advances in Experimental Medicine and Biology

Volumn 704, Issue , 2011, Pages 987-1009

  Chahl, Loris A ^a,b  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Anxiety; Depression; Schizophrenia; TRP channels; TRPC; TRPV

Indexed keywords

4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; ANTINOCICEPTIVE AGENT; CALCIUM ION; CANNABINOID; CANNABINOID 1 RECEPTOR; CAPSAICIN; CAPSAZEPINE; HYPERFORIN; RIMONABANT; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL 1; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TRANSIENT RECEPTOR POTENTIAL CHANNEL 5; TRANSIENT RECEPTOR POTENTIAL CHANNEL 6; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 ANTAGONIST; VANILLOID RECEPTOR 2; VANILLOID RECEPTOR 3;

ANTINOCICEPTION; ANXIETY; ANXIETY DISORDER; CALCIUM TRANSPORT; COGNITIVE DEFECT; CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG MECHANISM; DRUG TARGETING; HUMAN; LONG TERM POTENTIATION; MENTAL DISEASE; MENTAL STRESS; NERVE CELL DIFFERENTIATION; NERVE CELL PLASTICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION; TRANQUILIZING ACTIVITY; ANIMAL; BRAIN; PHYSIOLOGY; REVIEW;

ANIMALS; BRAIN; HUMANS; MENTAL DISORDERS; TRANSIENT RECEPTOR POTENTIAL CHANNELS;

EID: 79959772796     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-94-007-0265-3_51     Document Type: Conference Paper

References (176)

1. Montell C, Birnbaumer L, Flockerzi V, Bindels RJ, Bruford EA, Caterina MJ, Clapham DE, Harteneck C, Heller S, Julius D, Kojima I, Mori Y, Penner R, Prawitt D, Scharenberg AM, Schultz G, Shimizu N, Zhu MX (2002) A unified nomenclature for the superfamily of TRP cation channels. Mol Cell 9:229-231
2. Clapham DE, Montell C, Schultz G, Julius D (2003) International Union of Pharmacology. XLIII. Compendium of voltage-gated ion channels: Transient receptor potential channels. Pharmacol Rev 55:591-596
3. Owsianik G, D'hoedt D, Voets T, Nilius B (2006) Structure-function relationship of the TRP channel superfamily. Rev Physiol Biochem Pharmacol 156:61-90
4. Clapham DE (2003) TRP channels as cellular sensors. Nature 426:517-524
5. Liman ER, Corey DP, Dulac C (1999) TRP2: A candidate transduction channel for mammalian pheromone sensory signaling. Proc Natl Acad Sci USA 96:5791-5796
6. Riccio A, Medhurst AD, Mattei C, Kelsell RE, Calver AR, Randall AD, Benham CD, Pangalos MN (2002) mRNA distribution analysis of human TRPC family in CNS and peripheral tissues. Brain Res Mol Brain Res 109:95-104
7. Martorana A, Giampa C, De March Z, Viscomi MT, Patassini S, Sancesario G, Bernardi G, Fusco FR (2006) Distribution of TRPC1 receptors in dendrites of rat substantia nigra: A confocal and electron microscopy study. Eur J Neurosci 24:732-738
8. Giampa C, De March Z, Patassini S, Bernardi G, Fusco FR (2007) Immunohistochemical localization of TRPC6 in the rat substantia nigra. Neurosci Lett 424:170-174
9. De March Z, Giampa C, Patassini S, Bernardi G, Fusco FR (2006) Cellular localization of TRPC5 in the substantia nigra of rat. Neurosci Lett 402:35-39
10. Fusco FR, Martorana A, Giampa C, De March Z, Vacca F, Tozzi A, Longone P, Piccirilli S, Paolucci S, Sancesario G, Mercuri NB, Bernardi G (2004) Cellular localization of TRPC3 channel in rat brain; preferential distribution to oligodendrocytes. Neurosci Lett 365: 137-142
11. Zechel S,Werner S, von Bohlen und Halbach O (2007) Distribution of TRPC4 in developing and adult murine brain. Cell Tissue Res 328:651-656
12. Tai Y, Feng S, Du W, Wang Y (2009) Functional roles of TRPC channels in the developing brain. Pflügers Arch Eur J Physiol 458:283-289
13. Tai Y, Feng S, Ge R, Du W, Zhang X, He Z, Wang Y (2008) TRPC6 channels promote dendritic growth via the CaMKIV-CREB pathway. J Cell Sci 121:2301-2307
14. Talavera K, Nilius B, Voets T (2008) Neuronal TRP channels: Thermometers, pathfinders and life-savers. Trends Neurosci 31:287-295
15. Hartmann J, Dragicevic E, Adelsberger H, Henning HA, Sumser M, Abramowitz J, Blum R, Dietrich A, Freichel M, Flockerzi V, Birnbaumer L, Konnerth A (2008) TRPC3 channels are required for synaptic transmission and motor coordination. Neuron 59:392-398
16. Riccio A, Li Y, Moon J, Kim K-S, Smith KS, Rudolph U, Gapon S, Yao GL, Tsvetkov E, Rodig SJ, Veer AV,Meloni EG, CarlezonWA, Bolshakov VY, Clapham DE (2009) Essential role for TRPC5 in amygdala function and fear-related behaviour. Cell 137:761-772
17. Dhaka A, Viswanath V, Patapoutian A (2006) TRP ion channels and temperature sensation. Annu Rev Neurosci 29:135-161
18. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 389:816-824
19. Todaka H, Taniguchi J, Satoh J, Mizuno A, Suzuki M (2004) Warm temperature-sensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia. J Biol Chem 279:35133-35138
20. Moqrich A, Hwang SW, Earley TJ, Petrus MJ, Murray AN, Spencer KS, Andahazy M, Story GM, Patapoutian A (2005) Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307:1468-1472
21. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, Patapoutian AA (2002) TRP channel that senses cold stimuli and menthol. Cell 108:705-715
22. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, Patapoutian A (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112:819-829
23. Kauer JA, Gibson HE (2009) Hot flash: TRPV channels in the brain. Trends Neurosci 32:215-224
24. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21:531-543
25. Tominaga M, Tominaga T (2005) Structure and function of TRPV1. Pflugers Arch Eur J Physiol 451:143-150
26. Szallasi A, Cortright DN, Blum CA, Eid SR (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6:357-372
27. Mezey E, Toth ZE, Cortright DN, Arzubi MK, Krause JE, Elde R, Guo A, Blumberg PM, Szallasi A (2000) Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and the VR1-like immunoreactivity in the central nervous system of the rat and human. Proc Natl Acad Sci USA 97:3655-3660
28. Szabo T, Biro T, Gonzalez AF, Palkovits M, Blumberg PM (2002) Pharmacological characterization of vanilloid receptor located in the brain. Brain Res Mol Brain Res 98:51-57
29. Cristino L, de Petrocellis L, Pryce G, Baker D, Guglielmotti V, Di Marzo V (2006) Immunohistochemical localization of cannabinoid type1 and vanilloid transient receptor potential vanilloid type 1 receptors in mouse brain. Neuroscience 139:1405-1415
30. Sanchez JF, Krause JE, Cortwright DN (2001) The distribution and regulation of vanilloid receptor VR1 and VR1 5' splice variant RNA expression in rat. Neuroscience 107:373-381
31. Roberts JC, Davis JB, Benham CD (2004) (3H)Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res 995:176-183
32. Toth A, Boczan J, Kedei N, Lizanecz E, Bagi Z, Papp Z, Edes I, Csiba L, Blumberg PM (2005) Expression and distribution of vanilloid receptor 1 (TRPV1) in the adult rat brain. Brain Res Mol Brain Res 135:162-168
33. Liapi A, Wood JN (2005) Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TRPV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur J Neurosci 22:825-834
34. Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R, Shohami E, Spatz M (2004) Human brain endothelium: Coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res 132:87-92
35. Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258:1946-1949
36. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, Davis JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129:227-230
37. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452-457
38. Starowicz K, Nigam S, Di Marzo V (2007a) Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 114:13-33
39. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405:183-187
40. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306-313
41. Keeble J, Russell F, Curtis B, Starr A, Pinter E, Brain SD (2005) Involvement of transient receptor potential vanilloid 1 in the vascular and hyperalgesic components of joint inflammation. Arthritis Rheum 52:3248-3256
42. Ghilardi JR, Rohrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, Mantyh PW (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126-3131
43. Jia Y,McLeod RL, Hey JA (2005) TRPV1 receptor: A target for the treatment of pain, cough, airway disease and urinary incontinence. Drug News Perspect 18:165-171
44. Gunthorpe MJ, Szallasi A (2008) Peripheral TRPV1 receptors as targets for drug development: New molecules and mechanisms. Curr Pharm Des 14:32-41
45. Starowicz K, Cristino L, DiMarzo V (2008) TRPV1 receptors in the central nervous system: Potential for previously unforeseen therapeutic applications. Curr Pharm Des 14:42-54
46. Krishnan V, Nestler EJ (2008) The molecular neurobiology of depression. Nature 455: 894-902
47. Yulug B, Ozan E, Gönül SAS, Kilic E (2009) Brain-derived neurotrophic factor, stress and depression: A minireview. Brain Res Bull 78:267-269
48. DrevetsWC (2001) Neuroimaging and neuropathological studies of depression: Implications for the cognitive-emotional features of mood disorders. Curr Opin Neurobiol 11:240-249
49. Sheline YI (2003) Neuroimaging studies of mood disorder effects on the brain. Biol Psychiatry 54:338-352
50. Harrison PJ (2002) The neuropathology of primary mood disorder. Brain 125:1428-1449
51. Ressler KJ, Mayberg HS (2007) Targeting abnormal neural circuits in mood and anxiety disorders: From the laboratory to the clinic. Nat Neurosci 10:1116-1124
52. Mayberg HS, Lozano AM, Voon V, McNeely HE, Seminowicz D, Hamani C, Schwalb JM, Kennedy SH (2005) Deep brain stimulation for treatment-resistant depression. Neuron 45:651-660
53. Schlaepfer TE, Cohen MX, Frick C, Kosel M, Brodesser D, Axmacher N, Joe AY, Kreft M, Lenartz D, Sturm V (2008) Deep brain stimulation to reward circuitry alleviates anhedonia in refractory major depression. Neuropsychopharmacology 33:368-377
54. Kennedy SH (2008) Core symptoms of major depressive disorder: Relevance to diagnosis and treatment. Dialogues Clin Neurosci 10:271-277
55. Leuner K, Kazanski V, Muller M, Essin K, Henke B, Gollasch M, Harteneck C, Muller WE (2007) Hyperforin - a key constituent of St John's wort specifically activates TRPC6 channels. FASEB J 21:4101-4111
56. Kasckow JW, Mulchahey JJ, Geracioti TD (2004) Effects of the vanilloid agonist olvanil and antagonist capsazepine on rat behaviours. Biol Psychiatry 28:291-295
57. Marsch R, Foeller E, Rammes G, Bunck M, Kössl M, Holsboer F, Zieglgänsberger W, Landgraf R, Lutz B, Wotjak CT (2007) Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J Neurosci 27:832-839
58. Santos CJPA, Stern CAJ, Bertoglio LJ (2008) Attenuation of anxiety-related behaviour after the antagonism of transient receptor potential vanilloid type 1 channels in the rat ventral hippocampus. Behav Pharmacol 19:357-360
59. Bandler R, Keay KA, Floyd N, Price J (2000) Central circuits mediating patterned autonomic activity during active vs. passive emotional coping. Brain Res Bull 53:95-104
60. Moreira FA, Aguiar DC, Guimarães FS (2007) Anxiolytic-like effect of cannabinoids injected into the rat dorsolateral periaqueductal gray. Neuropharmacology 52:958-965
61. Maione S, Bisogno T, De Novellis V, Palazzo E, Cristino L, Valenti M, Petrosino S, Guglielmotti V, Rossi F, Di Marzo V (2006) Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid type 1 and transient receptor potential type-1 receptors. J Pharmacol Exp Ther 316:969-982
62. Terzian ALB, Aguiar DC, Guimarães FS, Moreira FA (2009) Modulation of anxiety-like behaviour by transient receptor potential vanilloid type 1 (TRPV1) channels located in the dorsolateral periaqueductal gray. Eur Neuropsychopharmacol 19:188-195
63. Szallasi A, Blumberg PM (1999) Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 51:159-211
64. Szallasi A, Di Marzo V (2000) New perspectives on enigmatic vanilloid receptors. Trends Neurosci 23:491-497
65. Micale V, Cristino L, Tamburella A, Petrosino S, Leggio GM, Drago F, Di Marzo V (2009) Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34:593-606
66. Willner P (2005) Chronic mild stress (CMS) revisited: Consistency and behaviouralneurobiological concordance in the effects of CMS. Neuropsychobiology 52:90-110
67. Holderbach R, Clark K, Moreau J-L, Bischofberger J, Normann C (2007) Enhanced longterm synaptic depression in an animal model of depression. Biol Psychiatry 62:92-100
68. Howland JG, Wang YT (2008) Synaptic plasticity in learning and memory: Stress effects in the hippocampus. Prog Brain Res 169:145-158
69. Wong TP, Howland JG, Robillard JM, Ge Y, Yu W, Titterness AK, Brebner K, Liu L, Weinberg J, Christie BR, Phillips AG, Wang YT (2007) Hippocampal long-term depression mediates acute stress-induced spatial memory retrieval impairment. Proc Natl Acad Sci USA 104:11471-11476
70. Xu L, Anwyl R, Rowan MJ (1997) Behavioral stress facilitates the induction of long-term depression in the hippocampus. Nature 387:497-500
71. Li H-B, Mao R-R, Zhang J-C, Yang Y, Cao J, Xu L (2008) Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol Psychiatry 64:286-292
72. Gunthorpe MJ, Rami HK, Jerman JC, Smart D, Gill CH, Soffin EM, Luis Hannan S, Lappin SC, Egerton J, Smith GD,Worby A, Howett L, Owen D, Nasir S, Davies CH, Thompson M, Wyman PA, Randall AD, Davis JB (2004) Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacology 46:133-149
73. Di Marzo V, Gobbi G, Szallasi A (2008) Brain TRPV1: A depressing TR(i)P down memory lane? Trends Pharmacol Sci 29:594-600
74. Gibson HE, Edwards JG, Page RS, Van Hook MJ, Kauer JA (2008) TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57:746-759
75. Alter BJ, Gereau RW (2008) Hotheaded: TRPV1 as mediator of hippocampal synaptic plasticity. Neuron 57:629-631
76. Maione S, Cristino L,Migliozzi AL, Georgiou AL, Starowicz K, Salt TE, Di Marzo V (2009) TRPV1 channels control synaptic plasticity in the developing superior colliculus. J Physiol 587:2521-2535
77. Wainwright A, Rutter AR, Seabrook GR, Reilly K, Oliver KR (2004) Discrete expression of TRPV2 within the hypothalamo-neurohypophysial system: Implications for regulatory activity within the hypothalamic-pituitary-adrenal axis. J Comp Neurol 474:24-42
78. Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, Kashman Y, Huang SM, Lee H, Shohami E, Mackie K, Caterina MJ, Walker JM, Fride E, Mechoulam R (2008) Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J 22:3024-3034
79. First MB, Frances A, Pincus HA (2002) DSM-IV-TR. handbook of differential diagnosis. American Psychiatric Association Publishing, Washington, DC 80. Freedman R (2003) Schizophrenia. N Engl J Med 349:1738-1749
80. Schwab SG, Wildenauer DB (2009) Update on key previously proposed candidate genes for schizophrenia. Curr Opin Psychiatry 22:147-153
81. Mei L, Xiong WC (2008) Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9:437-452
82. Harrison PJ (2007) Schizophrenia susceptibility genes and neurodevelopment. Biol Psychiatry 61:1119-1120
83. O'Tuathaigh CMP, Babovic D, O'Meara G, Clifford JJ, Croke DT, Waddington JL (2007) Susceptibility genes for schizophrenia: Characterization of mutant mouse models at the level of phenotypic behaviour. Neurosci Biobehav Rev 31:60-78
84. Chen J, Lipska BK, Weinberger DR (2006) Genetic mouse models of schizophrenia: From hypothesis-based to susceptibility gene-based models. Biol Psychiatry 59:1180-1188
85. Ross CA, Margolis RL, Reading SAJ, Pletnikov M, Coyle JT (2006) Neurobiology of schizophrenia. Neuron 52:139-153
86. Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson K (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892
87. Li D, Collier DA, He L (2006) Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15:1995-2002
88. Munafó MR, Thiselton DL, Clark TG, Flint J (2006) Association of the NRG1 gene and schizophrenia: A meta-analysis. Mol Psychiatry 11:539-546
89. Munafó MR, Attwood AS, Flint J (2008) Neuregulin 1 genotype and schizophrenia. Schizophrenia Bull 34:9-12
90. Hashimoto R, Straub RE, Weickert CS, Hyde TM, Kleinman JE, Weinberger DR (2004) Expression analysis of neuregulin-1 in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry 9:299-307
91. Law AJ, Lipska BK, Weickert CS, Hyde TM, Straub RE, Hashimoto R, Harrison PJ, Kleinman JE, Weinberger DR (2006) Neuregulin 1 transcripts are differentially expressed in schizophrenia and regulated by 5' SNPs associated with the disease. Proc Natl Acad Sci USA 103:6747-6752
92. Law AJ, Kleinman JE, Weinberger DR, Weickert CS (2007) Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 16:129-141
93. Silberberg G, Darvasi A, Pinkas-Kramarski R, Navon R (2006) The involvement of ErbB4 with schizophrenia: Association and expression studies. Am J Med Genet 141B:142-148
94. Schlaepfer TE, Harris GJ, Tien AY, Peng LW, Lee S, Federman EB, Chase GA, Barta PE, Pearlson GD (1994) Decreased regional cortical gray matter volume in schizophrenia. Am J Psychiatry 151:842-848
95. Selemon LD, Kleinman JE, Herman MM, Goldman-Rakic PS (2002) Smaller frontal gray matter volume in post-mortem schizophrenic brains. Am J Psychiatry 159:1983-1991
96. McDonald C, Grech A, Toulopoulou T, Schulze K, Chapple B, Sham P,WalsheM, Sharma T, Sigmundsson T, Chintis X, Murray RM (2002) Brain volumes in familial and non-familial schizophrenic probands and their unaffected relatives. Am J Med Genet (Neuropsychiatr Genet) 114:616-625
97. Shenton ME, Kikinis R, Jolesz FA, Pollak SD, Lemay M, Wible CG, Hokama H, Martin J, Metcalf D, Coleman M, McCarley RW (1992) Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. New Engl J Med 327:604-612
98. McCarley RW,Wilbe CG, Frumin M, Hirayasu Y, Levitt JJ, Fischer IA, Shenton ME (1999) MRI anatomy of schizophrenia. Biol Psychiatry 45:1099-1119
99. Selemon LD, Rajkowska G, Goldman-Rakic PS (1995) Abnormally high neuronal density in the schizophrenic cortex. A morphometric analysis of prefrontal area 9 and occipital area 17. Arch Gen Psychiatry 52:805-820
100. Selemon LD, Rajkowska G, Goldman-Rakic PS (1998) Elevated neuronal density in prefrontal area 46 in brains from schizophrenic patients: Application of a 3-dimensional, stereologic counting method. J Comp Neurol 392:402-412
101. Selemon LD, Goldman-Rakic PS (1999) The reduced neuropil hypothesis: A circuit based model of schizophrenia. Biol Psychiatry 45:17-25
102. Buxhoeveden D, Roy E, Switala A (2000) Reduced interneuronal space in schizophrenia. Biol Psychiatry 47:681-683
103. Casanova MF, De Zeeuw L, Switala A, Kreczmanski P, Korr H, Ulfig N, Heinsen H, Steinbusch HWM, Schmitz C (2005) Mean cell spacing abnormalities in the neocortex of patients with schizophrenia. Psychiatry Res 133:1-12
104. Rajkowska G, Selemon LD, Goldman-Rakic PS (1998) Neuronal and glial somal size in the prefrontal cortex: A post-mortem morphometric study of schizophrenia and Huntington disease. Arch Gen Psychiatry 55:215-224
105. Pajonk F-G, Wobrock T, Gruber O, Scherk H, Berner D, Kaizl I, Kierer A, Müller S, Oest M, Meyer T, Backens M, Schneider-Axmann T, Thornton AE, Honer WG, Falkai P (2010) Hippocampal plasticity in response to exercise in schizophrenia. Arch Gen Psychiatry 67:133-143
106. Seeman P (1992) Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4. Neuropsychopharmacology 7:261-284
107. Marsden CA (2006) Dopamine: The rewarding years. Br J Pharmacol 147:S136-S144
108. Lewis DA, Gonzalez-Burgos G (2006) Pathophysiologically based treatment interventions in schizophrenia. Nat Med 12:1016-1022
109. Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-179
110. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: Toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215-233
111. du Bois TM, Huang X-F (2007) Early brain development disruption from NMDA receptor hypofunction: Relevance to schizophrenia. Brain Res Rev 53:260-270
112. Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98:427-436
113. Vollenweider FX, Vontobel P, Oye I, Hell D, Leenders KL (2000) Effects of (S)-ketamine on striatal dopamine: A [11C]raclopride PET study of a model psychosis in humans. J Psychiatric Res 34:35-43
114. Hahn CG, Wang HY, Cho DS, Talbot K, Gur RE, Berrettini WH, Bakshi K, Kamins J, Borgmann-Winter KE, Siegel SJ, Gallop RJ, Arnold SE (2006) Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12: 824-828
115. Strubing C, Krapivinsky G, Krapivinsky L, Clapham DE (2003) Formation of novel TRPC channels by complex subunit interactions in embryonic brain. J Biol Chem 278: 39014-39019
116. Greka A, Navarro B, Oancea E, Duggan A, Clapham DE (2003) TRPC5 is a regulator of hippocampal neurite length and growth cone morphology. Nat Neurosci 6:837-845
117. Bezzerides VJ, Ramsey IS, Kotecha S, Greka A, Clapham DE (2004) Rapid vesicular translocation and insertion of TRP channels. Nat Cell Biol 6:709-720
118. Hui H, McHugh D, Hannan M, Zeng F, Xu S-Z, Khan S-U-H, Levenson R, Beech DJ,Weiss JL (2006) Calcium-sensing mechanism in TRPC5 channels contributing to retardation of neurite outgrowth. J Physiol 572:165-172
119. Li Y, Jia YC, Cui K, Li N, Zheng ZY, Wang YZ, Yuan XB (2005) Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. Nature 434:894-898
120. Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000) Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28:53-67
121. Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, Becker KG, Freed WJ (2002) Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: A preliminary study. Schizophrenia Res 58:11-20
122. Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, Erberwine JH (2002) Gene expression profile for schizophrenia: Discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry 59:631-640
123. Munsch T, Freichel M, Flockerzi V, Pape HC (2003) Contribution of transient receptor potential channels to the control of GABA release from dendrites. Proc Natl Acad Sci USA 100:16065-16070
124. Krapivinsky G, Mochida S, Krapivinsky L, Cibulsky SM, Clapham DE (2006) The TRPM7 ion channel functions in cholinergic synaptic vesicles and affects transmitter release. Neuron 52:485-496
125. Marinelli S, Di Marzo V, Florenzano F, Fezza F, Viscomi MT, van der Stelt M, Bernardi G, Molinari M, Maccarrone M, Mercuri NBN- (2007) Arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32:298-308
126. Marinelli S, Pascucci T, Bernardi G, Puglisi-Allegra S, Mercuri NB (2005) Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxiousinduced dopamine release in the nucleus accumbens. Neuropsychopharmacology 30: 864-870
127. Musella A, De Chiara V, Rossi S, Prosperetti C, Bernardi G, Maccarrone M, Centonze D (2009) TRPV1 channels facilitate glutamate transmission in the striatum. Mol Cell Neurosci 40:89-97
128. Li DP, Chen SR, Pan HL (2004) VR1 receptor activation induces glutamate release and postsynaptic firing in the paraventricular nucleus. J Neurophysiol 92:1807-1816
129. Starowicz K, Maione S, Cristino L, Palazzo E, Marabese I, Rossi F, de Novellis V, Di Marzo V (2007b) Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J Neurosci 27:13739-13749
130. Xing J, Li J (2007) TRPV1 receptor mediates glutamatergic synaptic input to dorsolateral periaqueductal gray (dl-PAG) neurons. J Neurophysiol 97:503-511
131. Yang K, Kumamoto E, Furue H, Yoshimura M (1998) Capsaicin facilitates excitatory but not inhibitory synaptic transmission in substantia gelatinosa of the rat spinal cord. Neurosci Lett 255:135-138
132. Lee J, Di Marzo V, Brotchie JM (2006) A role for vanilloid receptor 1 (TRPV1) and endocannabinoid signaling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology 51:557-565
133. de Lago E, de Miguel R, Lastres-Becker I, Ramos JA, Fernandez-Ruiz J (2004) Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: In vivo and in vitro evidence. Brain Res 1007:152-159
134. Jordt SE, Julius D (2002) Molecular basis for species-specific sensitivity to 'hot' chili peppers. Cell 108:421-430
135. Tzavara ET, Li DL, Moutsimilli L, Bisogno T, Di Marzo V, Phebus LA, Nomikos GG, Giros B (2006) Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: Therapeutic implications. Biol Psychiatry 59:508-515
136. Panlilio LV, Mazzola C, Medalie J, Hahn B, Justinova Z, Drago F, Cadet JL, Yasar S, Goldberg SR (2009) Anandamide-induced behavioural disruption through a vanilloiddependent mechanism in rats. Psychopharmacology 203:529-538
137. Akopian AN, Ruparel NB, Jeske NA, Patwardhan A, Hargreaves KM (2008) Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia. Trends Pharmacol Sci 30:79-84
138. Kim SR, Lee DY, Chung ES, Oh UT, Kim SU, Jin BK (2005) Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. J Neurosci 25:662-671
139. Kim SR, Bok E, Chung YC, Chung ES, Jin BK (2008) Interactions between CB1 receptors and TRPV1 channels mediated by 12-HPETE are cytotoxic to mesencephalic dopaminergic neurons. Br J Pharmacol 155:253-264
140. Pegorini S, Braida D, Verzoni C, Guerini-Rocco C, Consalez GG, Croci L, Sala M (2005) Capsaicin exhibits neuroprotective effects in a model of transient global ischemia in Mongolian gerbils. Br J Pharmacol 144:727-735
141. Pegorini S, Zani A, Braida D, Guerinin-Rocco C, Sala M (2006) Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol 147:552-559
142. Kim SR, Chung YC, Chung ES, Park KW, Won SY, Bok E, Park ES, Jin BK (2007) Roles of transient receptor potential vanilloid subtype 1 and cannabinoid type 1 receptors in the brain: Neuroprotection versus neurotoxicity. Mol Neurobiol 35:245-254
143. Degenhardt L, Hall W (2006) Is cannabis use a contributory cause of psychosis? Canad. J Psychiatry 51:556-565
144. Laviolette SR, Grace AA (2006) The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: Implications for schizophrenia and addiction. Cell Mol Life Sci 63:1597-1613
145. Sundram S (2006) Cannabis and neurodevelopment: Implications for psychiatric disorders. Human Psychopharmacol 21:245-254
146. Malone DT, Hill MN, Rubino T (2010) Adolescent cannabis use and psychosis: Epidemiology and neurodevelopmental models. Brit J Pharmacol 160:511-522
147. Harkany T, Guzman M, Galve-Roperh I, Berghuis P, Devi LA, Mackie K (2007) The emerging functions of endocannabinoid signaling during CNS development. Trends Pharmacol Sci 28:83-92
148. Chavarria-Siles I, Contreras-Rojas J, Hare E,Walss-Bass C, Quezada P, Dassori A, Contreras S, Medina R, Ramirez M, Salazar R, Raventos H, Escamilla MA (2008) Cannabinoid receptor 1 gene (CNR1) and susceptibility to a quantitative phenotype for hebephrenic schizophrenia. Am J Med Genet B Neuropsychiatr Genet 147:279-284
149. Ishiguro H, Horiuchi Y, Ishikawa M, Koga M, Imai K, Suzuki Y, Morikawa M, Inada T, Watanabe Y, Takahashi M, Someya T, Ujike H, Iwata N, Ozaki N, Onaivi ES, Kunugi H, Sasaki T, Itokawa M, Arai M, Niizato K, Iritani S, Naka I, Ohashi J, Kakita A, Takahashi H, Nawa H, Arinami T (2010) Brain cannabinoid CB2 receptor in schizophrenia. Biol Psychiatry 67:974-982
150. Hermesh H, Shiloh R, Epstein Y, Manaim H,Weizman A, Munitz H (2000) Heat intolerance in patients with chronic schizophrenia maintained with antipsychotic drugs. Am J Psychiatry 157:1327-1329
151. Chong TWH, Castle DJ (2004) Layer upon layer: Thermoregulation in schizophrenia. Schizophrenia Res 69:149-157
152. Schwartz PJ, Erk SD (2004) Regulation of central dopamine-2 receptor sensitivity by a proportional control thermostat in humans. Psychiatry Res 127:19-26
153. Shiloh R, Weizman A, Epstein Y, Rosenberg SL, Valevski A, Dorfman-Etrog P, Wiezer N, Katz N, Munitz H, Hermesh H (2001) Abnormal thermoregulation in drug-free male schizophrenia patients. Eur Neuropsychopharmacol 11:285-288
154. Lee TF, Mora F, Myers RD (1985) Dopamine and thermoregulation: An evaluation with special reference to dopaminergic pathways. Neurosci Biobehav Rev 9:589-598
155. Barros RCH, Branco LGS, Carnio EC (2004) Evidence for thermoregulation by dopamine D1 and D2 receptors in the anteroventral preoptic region during normoxia and hypoxia. Brain Res 1030:165-171
156. Karlsson U, Sundgren-Andersson AK, Johansson S, Krupp JJ (2005) Capsaicin augments synaptic transmission in the rat medial preoptic nucleus. Brain Res 1043:1-11
157. Szolcsanyi J (2004) Forty years in capsaicin research for sensory pharmacology and physiology. Neuropeptides 38:377-384
158. Kudoh A, Ishihara H, Matsuki A (2000) Current perception thresholds and postoperative pain in schizophrenic patients. Reg Anesth Pain Med 25:475-479
159. Blumensohn R, Ringler D, Eli I (2002) Pain perception in patients with schizophrenia. J Nerv Mental Dis 190:481-483
160. Hooley JM, Delgado ML (2001) Pain insensitivity in the relatives of schizophrenia patients. Schizophrenia Res 47:265-273
161. Bonnot O, Anderson GM, Cohen D, Willer JC, Tordjman S (2009) Are patients with Schizophrenia insensitive to pain? a reconsideration of the question. Clin J Pain 25:244-252
162. Potvin S, Marchand S (2008) Hypoalgesia in schizophrenia is independent of antipsychotic drugs: A systematic quantitative review of experimental studies. Pain 138:70-78
163. Ren K, Williams GM, Ruda MA, Dubner R (1994) Inflammation and hyperalgesia in rats neonatally treated with capsaicin: Effects on two classes of nociceptive neurons in the superficial dorsal horn. Pain 59:287-300
164. Holzer P (1991) Capsaicin: Cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43:143-201
165. Hwang SJ, Burette A, Rustioni A, Valtschanoff JG (2004) Vanilloid receptor VR1-positive primary afferents are glutamatergic and contact spinal neurons that co-express neurokinin receptor NK1 and glutamate receptors. J Neurocytology 33:321-329
166. Bolcskei K, Helyes Z, Szabo A, Sandor K, Elekes K, Nemeth J, Almasi R, Pinter E, Petho G, Szolcsanyi J (2005) Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. Pain 117:368-376
167. Zimmermann K, Leffler A, Fischer MMJ, Messlinger K, Nau C, Reeh PW (2005) The TRPV1/2/3 activator 2-aminoethoxydiphenyl borate sensitizes native nociceptive neurons to heat in wildtype but not TRPV1 deficient mice. Neuroscience 135:1277-1284
168. Waldo MC (1999) Co-distribution of sensory gating and impaired niacin flush response in the parents of schizophrenics. Schizophrenia Res 40:49-53
169. Messamore E, Hoffman WE, Janowsky A (2003) The niacin skin flush abnormality in schizophrenia: A quantitative dose-response study. Schizophrenia Res 62:251-258
170. Sadaka Y, Weinfeld E, Lev DL, White EL (2003) Changes in mouse barrel synapses consequent to sensory deprivation from birth. J Comp Neurol 457:75-86
171. Janscó G, Király E, Janscó-Gábor A (1977) Pharmacologically induced selective degeneration of chemosensitive primary sensory neurons. Nature (London) 270:741-743
172. Newson P, Lynch-Frame A, Roach R, Bennett S, Carr V, Chahl LA (2005) Intrinsic sensory deprivation induced by neonatal capsaicin treatment induces changes in rat brain and behaviour of possible relevance to schizophrenia. Brit J Pharmacol 146:408-418
173. Chahl LA (2007) TRP's: Links to schizophrenia? Biochim Biophys Acta 1772:968-977
174. Ritter S, Dinh TT (1988) Capsaicin-induced neuronal degeneration: Silver impregnation of cell bodies, axons, and terminals in the central nervous system of the adult rat. J Comp Neurol 271:79-90
175. Ritter S, Dinh TT (1990) Capsaicin-induced neuronal degeneration in the brain and retina of preweanling rats. J Comp Neurol 296:447-461
176. Zavitsanou K, Dalton VS, Wang H, Newson P, Chahl LA (2010) Receptor changes in brain tissue of rats treated as neonates with capsaicin. J Chem Neuroanat 39:248-255